Doximity Stock Jumps 78% After CEO Reveals AI Search Tool Generates 10x Returns on Investment
6 Sources
[1]
Shares of this digital medical platform were up more than 100% at one point. Here's what's driving it
The incredible surge was boosted by short sellers having to unwind a sizable bet against the company. Shares of medical platform Doximity more than doubled at one point in premarket trading Friday after some bold comments on the margin for its new AI search tool. CEO Jeffrey Tangney said the
[2]
Here's Why Doximity Stock Is Flying Today
Get personalized, AI-powered answers built on 27+ years of trusted expertise. Shares of Doximity are rocking higher Friday. The reason? AI. Doximity (DOCS) stock was up more than 45% at around $30 recently, rising as high as $40 in the opening minutes of the session, after the telehealth company
[3]
Doximity shares soar 60% after CEO says its AI can outperform Anthropic
Doximity shares surged after the healthcare platform highlighted the strong performance of its clinical AI, overshadowing an earnings miss. Investors cheered its AI capabilities, positioning the company as a specialised healthcare AI player despite mixed quarterly financial results. Doximity
[4]
Why Is Doximity Stock Soaring Friday? - Doximity (NYSE:DOCS)
Doximity CEO Says AI Is Unlocking A Bigger Market Than Expected During the earnings call, CEO Jeff Tangney said Doximity's artificial intelligence strategy is opening larger commercial opportunities than the company initially expected. He said AI Search is helping the company engage with senior
[5]
Why Doximity Stock is Up More Than 70% in After-Hours Trading Thursday - Doximity (NYSE:DOCS)
Digital health care company Doximity Inc (NYSE:DOCS) reported first-quarter financial results Thursday after market close. Here are the key highlights and why the stock is soaring after hours. Doximity Q1 Earnings Doximity reported first-quarter revenue of $156.6 million, up 7% year-over-year.
[6]
Why is Doximity stock skyrocketing 66% today? By Investing.com
Investing.com -- Doximity stock surged 66.0% in pre-open trading today after the company reported fiscal first-quarter 2027 results the prior evening that topped revenue expectations and prompted management to lift its full-year financial targets. Revenue came in at $156.6 million, a 7%
Share
Copy Link
Doximity stock skyrocketed over 78% after CEO Jeff Tangney disclosed that the company's AI search tool generates 10 times more revenue than it costs to operate. The physician-focused digital medical platform also reported that its clinical AI assistant outperformed competitors including Anthropic in independent testing, signaling major growth potential in the healthcare AI market.
Doximity Stock Surges on Exceptional AI Profitability
Doximity stock experienced a dramatic surge, jumping as much as 130% in premarket trading Friday before settling at a 78% gain, after CEO Jeff Tangney revealed unprecedented profitability metrics for the company's AI search tool
1
. Speaking during the company's first-quarter fiscal 2027 earnings call, Tangney disclosed that the digital medical platform is "earning more than 10 times per search in revenue than it costs"1
. This revelation transformed investor sentiment toward the physician-focused platform, which had been down 50% year-to-date before the announcement1
.
Source: Benzinga
The spectacular rally was amplified by a short squeeze, as approximately 17% of shares available for trading were sold short heading into the earnings results
1
. As short sellers scrambled to unwind their positions, it added fuel to Doximity's surge, pushing the stock from under $21 to as high as $40 in early trading2
.Clinical AI Assistant Outperforms Major Competitors
Doximity Ask, the company's clinical AI assistant, demonstrated superior performance in independent testing, achieving a 4.8% error rate in physician-focused testing compared to 13.6% for Anthropic's best model, Fable 5
3
. The platform outperformed OpenEvidence, Claude Fable 5, and other frontier models in a Stanford-Harvard study on clinical AI safety, recording the lowest clinical error rates and highest safety ratings among tested U.S.-based models3
4
.
Source: Benzinga
Tangney emphasized that the company is "seeing record AI usage while topping the first large-scale independent head-to-head trial of clinical AI vendors"
2
. This performance is driving adoption, with 165 health system clients now using Doximity's AI offerings4
.AI Strategy Unlocks Larger Addressable Market
The AI search tool is expanding Doximity's total addressable market beyond initial expectations. Tangney stated that "the [total addressable market] that this unlocks for us within health, within pharma has been a real surprise and upside for us"
1
. The AI strategy is helping the company engage with senior executives at pharmaceutical companies and "up-leveling our business across the board"4
.Workflow active prescriber growth exceeded 30% year-over-year, while AI search queries increased more than 25% sequentially
4
5
. CFO Matt Sonefeldt cited a "nascent but growing AI commercial pipeline" and said the company would increase AI investments during fiscal 2027 to support long-term growth opportunities2
4
.Related Stories
Strong Financial Performance and Raised Guidance
Doximity reported first-quarter revenues of $156.6 million, up 7% year-over-year and beating consensus estimates of $151.7 million
1
4
. Adjusted EBITDA reached $74.8 million, representing a 48% margin and exceeding expectations1
5
. The company raised its full-year revenue guidance by $6 million to between $671 million and $681 million, though analysts believe this conservative forecast doesn't yet reflect the full AI opportunity1
4
.Jessica Tassan at Piper Sandler noted that "the FY27 raise does not reflect a significant contribution from the expanding AI commercial pipeline"
1
, suggesting management is taking a conservative approach to AI search revenue projections. Michael Cherney at Leerink Partnerships wrote that the AI strategy is "reinforcing confidence that [Doximity's] elevated AI investments will ultimately support attractive long-term margins"1
.Market Repositioning as Healthcare AI Platform
Investors are now treating Doximity less like a traditional healthcare software company and more like a specialized AI platform for physicians
3
. The company ended the quarter with 127 pharmaceutical and hospital customers generating more than $500,000 in annual subscription revenue on a trailing 12-month basis4
. Watch for continued AI adoption metrics, expanding pharmaceutical partnerships, and whether Doximity can maintain its competitive edge in clinical AI safety as the healthcare AI market intensifies.References
Summarized by
Navi
[2]
Related Stories
Doximity's Stock Soars as AI Integration Boosts Performance and User Engagement
08 Feb 2025•Business and Economy
DocuSign Surges on Strong Q2 Results and AI-Powered Innovation
05 Sept 2025•Business and Economy
DigitalOcean's Q2 Earnings Surge Driven by AI Growth and Cloud Services
06 Aug 2025•Business and Economy
Recent Highlights
1
AI Hallucination Nearly Sparked US Military Confrontation With Chinese Ship in Middle East
Technology
2
Google Gemini Hacked Three Real Companies During Cybersecurity Testing, Raising AI Safety Concerns
Technology
3
OpenAI Claims AI Breakthrough on Navier-Stokes Problem, Sparking Math Community Crisis
Science and Research
Recent Highlights
Today's Top Stories
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Follow topics that matter to you and stay ahead.
